Hepatitis C virus infection and the risk of coronary disease

Clinical Infectious Diseases

Volumn 49, Issue 2, 2009, Pages 225-232

  Butt, Adeel A ^a,b,h   Xiaoqiang, Wang ^b   Budoff, Matthew ^c   Leaf, David ^d,e   Kuller, Lewis H ^b   Justice, Amy C ^f,g  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALCOHOL ABUSE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DRUG ABUSE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL;

ADULT; CORONARY DISEASE; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; VETERANS;

EID: 67651095598     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599371     Document Type: Article

References (44)

1. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350:430-6.
2. Sheehan J, Kearney PM, Sullivan SO, Mongan C, Kelly E, Perry IJ. Acute coronary syndrome and chronic infection in the Cork coronary care case-control study. Heart 2005;91:19-22.
3. Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ 2000; 163:49-56.
4. Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA. No association between hepatitis C virus seropositivity and acute myocardial infarction. Clin Infect Dis 2006; 43:e53-6.
5. Volzke H, Schwahn C, Wolff B, et al. Hepatitis B and C virus infection and the risk of atherosclerosis in a general population. Atherosclerosis 2004; 174:99-103.
6. Momiyama Y, Ohmori R, Kato R, Taniguchi H, Nakamura H, Ohsuzu F. Lack of any association between persistent hepatitis B or C virus infection and coronary artery disease. Atherosclerosis 2005; 181:211-3.
7. Tong DY, Wang XH, Xu CF, Yang YZ, Xiong SD. Hepatitis B virus infection and coronary atherosclerosis: results from a population with relatively high prevalence of hepatitis B virus. World J Gastroenterol 2005; 11:1292-6.
8. Vassalle C, Masini S, Bianchi F, Zucchelli GC. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 2004; 90:565-6.
9. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002;359:133-5.
10. Sawayama Y, Okada K, Maeda S, Ohnishi H, Furusyo N, Hayashi J. Both hepatitis C virus and Chlamydia pneumoniae infection are related to the progression of carotid atherosclerosis in patients undergoing lipid lowering therapy. Fukuoka Igaku Zasshi 2006; 97:245-55.
11. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T. Hepatitis C virus and atherosclerosis in patients with type 2 diabetes. JAMA 2003; 289: 1245-6.
12. Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003; 98:2064-71.
13. Sanyal AJ. Review article: non-alcoholic fatty liver disease and hepatitis C-risk factors and clinical implications. Aliment Pharmacol Ther 2005; 22:48-51.
14. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Nonalcoholic hepatic steatosis and its relation to increased plasma bio- markers of inflammation and endothelial dysfunction in non-diabetic men: role of visceral adipose tissue. Diabet Med 2005;22:1354-8.
15. Butt AA, Justice AC, Skanderson M, Rigsby M, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56:385-9.
16. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kwoh CK. Co- morbid medical and psychiatric illness and substance abuse in HCV- infected and uninfected veterans. J Viral Hepat 2007; 14:890-6.
17. Butt AA, Justice AC, Skanderson M, Good CB, Kwoh CK. Rates and predictors of HCV treatment in HCV-HIV coinfected persons. Aliment Pharmacol Ther 2006; 24:585-91.
18. Butt AA, Skanderson M, McGinnis KA, Kwoh CK, Justice AC. Real-life rates of treatment completion for HCV [abstract 281]. In: Program and abstracts of the 58th Annual Meeting of the American Association for the Study of Liver Diseases (Boston). 2007:364A.
19. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-10.
20. Kramer JR, Giordano TP, Souchek J, El Serag HB. Hepatitis C coin- fection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 2005; 42:309-14.
21. Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepa- tocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroen- terol 2005; 100:56-63.
22. Giordano TP, Kramer JR, Souchek J, Richardson P, El Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164:2349-54.
23. Fultz SL, Skanderson M, Mole LA, et al. Development and verification of a "virtual" cohort using the National VA Health Information System. Med Care 2006;44(Suppl 2):S25-30.
24. Justice AC, Lasky E, McGinnis KA, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care 2006; 44(Suppl 2):S52-60.
25. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. The risk of diabetes in HIV infected veterans in the pre- and post- HAART era and the role of hepatitis C virus co-infection. Hepatology 2004;40:115-9.
26. Goulet JL, Fultz SL, McGinnis KA, Justice AC. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS 2005; 19(Suppl 3):S99-105.
27. McGinnis KA, Skanderson M, Levin F, Brandt C, Erdos J, Justice AC. Comparison of two VA laboratory data repositories indicates that missing data vary despite originating from the same source. Med Care 2009;47:121-4.
28. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas M, Crystal S, Justice AC. Increased chronic obstructive pulmonary disease among HIV positive compared to HIV negative veterans. Chest 2006; 130: 1326-33.
29. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-74.
30. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6:508-19.
31. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
32. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 2003; 10:63-71.
33. Nascimento MM, Bruchfeld A, Suliman ME, et al. Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. Braz J Med Biol Res 2005; 38:783-8.
34. Riordan SM, Skinner NA, Kurtovic J, et al. Toll-like receptor expression in chronic hepatitis C: correlation with pro-inflammatory cytokine levels and liver injury. Inflamm Res 2006; 55:279-85.
35. Rios-Olivares E, Vila LM, Reyes JC, et al. Impaired cytokine production and suppressed lymphocyte proliferation activity in HCV-infected cocaine and heroin ("speedball") users. Drug Alcohol Depend 2006;85: 236-43.
36. Elsurer R, Afsar B, Sezer S, Arat Z, Ozdemir FN, Haberal M. Malnutrition inflammation score is associated with coronary artery disease in hepatitis C virus-infected hemodialysis patients. Eur J Clin Nutr 2008; 62:1449-54.
37. Alyan O, Kacmaz F, Ozdemir O, et al. Hepatitis C infection is associated with increased coronary artery atherosclerosis defined by modified Reardon severity score system. Circ J 2008; 72:1960-5.
38. Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005; 12:81-5.
39. Marzouk D, Sass J, Bakr I, et al. Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut 2007;56: 1105-10.
40. Jarmay K, Karacsony G, Nagy A, SchaffZ. Changes in lipid metabolism in chronic hepatitis C. World J Gastroenterol 2005; 11:6422-8.
41. Siagris D, Christofidou M, Theocharis GJ, et al. Serum lipid pattern in chronic hepatitis C: histological and virological correlations. J Viral Hepat 2006; 13:56-61.
42. Gradman AH. Cardiac effects of cocaine: a review. Yale J Biol Med 1988;61:137-47.
43. Kolodgie FD, Virmani R, Cornhill JF, Herderick EE, Smialek J. Increase in atherosclerosis and adventitial mast cells in cocaine abusers: an alternative mechanism of cocaine-associated coronary vasospasm and thrombosis. J Am Coll Cardiol 1991; 17:1553-60.
44. Bauman JL, Grawe JJ, Winecoff AP, Hariman RJ. Cocaine-related sudden cardiac death: a hypothesis correlating basic science and clinical observations. J Clin Pharmacol 1994;34:902-11.